S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

Bibliographic Details
Main Authors:	M Telen, S Saraf, K Cruz, M Idowu, T Kalfa, I Osunkwo, R Hagar, J Geib, S Forsyth, P Schroeder, E Wu, P Kelly, R Brown
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000821404.03661.11

Internet